Strategic partnerships Leverage existing Bayer licensing and preclinical ERSO program to position as a partner for oncology target discovery and multi-target RNA therapeutics, offering collaboration on co-development or license-out opportunities to accelerate pipeline validation.

AI-powered discovery Highlight Systems Oncology’s AI-driven approach to cancer therapy discovery and its Arromer platform for rapid, tissue-targeted, self-delivering RNA therapeutics as a differentiator to attract collaboration with larger biotechs seeking faster cycle times.

Early-stage pipeline Focus on translating preclinical assets and the ERSO program into strategic BD targets for partnerships with pharma companies seeking novel mechanisms to address metastatic ER-positive breast cancer and other polygenic disease areas.

Global licensing Promote exclusive global license success with Bayer as a proof point for the company’s ability to secure high-value deals, signaling readiness for additional regional or cross-portfolio licensing discussions.

Market positioning Position the multimodal RNA platform as a platform technology with potential applicability across oncology and other polygenic diseases to attract strategic investments, co-development deals, and potential manufacturing or CRO partnerships to scale quickly.